Pelabresib Clinical Trials (2026): 8 Studies for Advanced Malignancies & Solid Tumor
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
8 Pelabresib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Advanced Malignancies & Solid Tumor) and 1,365 total planned enrollment. 3 Phase 3 Pelabresib trials are listed. 5 Pelabresib clinical trials are actively recruiting at 7 U.S. sites across 6 states. Most recent activity: NCT07357727 (Dec 2030).
Where to Participate: All Pelabresib Trial Sites in the U.S. (7 sites across 6 states)
Every actively recruiting Pelabresibtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | University of California LA | Los Angeles90095 | NCT06401356 | Map |
| FL | Mayo Clinic Jacksonville | Jacksonville32224 | NCT06401356 | Map |
| IL | Northwestern University | Chicago60611 | NCT06401356 | Map |
| MI | Uni Of Michigan Health System | Ann Arbor48109 | NCT06401356 | Map |
| NJ | Summit Medical Group | Berkeley Heights07922 | NCT07357727 | Map |
| NY | Mt Sinai Medical Center | New York10029-6574 | NCT06401356 | Map |
| NY | New York Presbyterian Hospital | New York10021 | NCT06401356 | Map |
Pelabresib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | Total |
|---|---|---|---|---|
| P1 | 3 | 1 | 4 | |
| P1/P2 | 1 | 1 | ||
| P3 | 2 | 1 | 3 |
Recruiting Pelabresib clinical trials (5)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07357727 | MANIFEST-3A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | P3 | Primary Myelofibrosis (PMF) | 460 | May 2026 |
| NCT07340138 | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | P1 | Primary Myelofibrosis (PMF) | 6 | Apr 2026 |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | P1 | Advanced Malignancies and Hepatic Impairment | 24 | Apr 2026 |
| NCT07340190 | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies | P1 | Advanced Malignancies | 24 | May 2026 |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | P3 | Hematologic Malignancy | 50 | Aug 2024 |
Pelabresib clinical trials by indication
Advanced Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07340190 | — | P1 | recruiting | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies |
| NCT05391022 | — | P1 | completed | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies |
Primary Myelofibrosis (PMF) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07357727 | MANIFEST-3 | P3 | recruiting | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
| NCT07340138 | — | P1 | recruiting | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis |
Myelofibrosis (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04603495 | MANIFEST-2 | P3 | active not recruiting | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) |
| NCT02158858 | — | P1/P2 | completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies |
Advanced Malignancies and Hepatic Impairment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07422610 | — | P1 | recruiting | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment |
Hematologic Malignancy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06401356 | — | P3 | recruiting | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib |
Pelabresib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MANIFEST-3 | NCT07357727 | P3 | recruiting | Primary Myelofibrosis (PMF) | 460 | — |
| MANIFEST-2 | NCT04603495 | P3 | active not recruiting | Myelofibrosis | 430 | PMID 40065169 |
All Pelabresib trials (8)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07357727 | MANIFEST-3 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | P3 | recruiting | 460 | Novartis Pharmaceuticals | May 2026 |
| NCT07340138 | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | P1 | recruiting | 6 | Novartis Pharmaceuticals | Apr 2026 | |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | P1 | recruiting | 24 | Novartis Pharmaceuticals | Apr 2026 | |
| NCT07340190 | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies | P1 | recruiting | 24 | Novartis Pharmaceuticals | May 2026 | |
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | P3 | recruiting | 50 | Novartis Pharmaceuticals | Aug 2024 | |
| NCT04603495 | MANIFEST-2 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | P3 | active not recruiting | 430 | Novartis Pharmaceuticals | Apr 2021 |
| NCT02158858 | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | P1/P2 | completed | 336 | Constellation Pharmaceuticals | Jul 2014 | |
| NCT05391022 | Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies | P1 | completed | 35 | Constellation Pharmaceuticals | Jul 2021 |
Pelabresib clinical trials: frequently asked questions
- How many Pelabresib clinical trials are there?
- 8 Pelabresib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 2 are marked completed.
- Are Pelabresib clinical trials recruiting in 2026?
- Yes — 5 Pelabresib trials are actively recruiting in 2026, with 7 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Pelabresib being studied for?
- Pelabresib is being studied for Advanced Malignancies, Solid Tumor, Myelofibrosis, Primary Myelofibrosis, Primary Myelofibrosis (PMF) and 21 more. The trials are grouped by indication on this page.
- What phase is Pelabresib in?
- Pelabresib clinical trials span 3 Phase 3, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Pelabresib clinical trials?
- The lead sponsor across the most Pelabresib trials is Novartis Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pelabresibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: